First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

Samuel Cytryn(Memorial Sloan Kettering Cancer Center), Ryan H. Moy(Memorial Sloan Kettering Cancer Center), Darren Cowzer(Memorial Sloan Kettering Cancer Center), Ronak Shah(Memorial Sloan Kettering Cancer Center), Joanne F. Chou(Memorial Sloan Kettering Cancer Center), Smita S. Joshi(Memorial Sloan Kettering Cancer Center), Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Steven B. Maron(Memorial Sloan Kettering Cancer Center), Avni M. Desai(Memorial Sloan Kettering Cancer Center), Jessica Yang(Memorial Sloan Kettering Cancer Center), Ryan Sugarman(Memorial Sloan Kettering Cancer Center), Devika Rao(Memorial Sloan Kettering Cancer Center), Zoe Goldberg(Memorial Sloan Kettering Cancer Center), Carmelina Charalambous(Memorial Sloan Kettering Cancer Center), M. A. Lapshina(Memorial Sloan Kettering Cancer Center), Ariel Antoine(Memorial Sloan Kettering Cancer Center), Fiona Socolow(Memorial Sloan Kettering Cancer Center), Nikhil Trivedi(Memorial Sloan Kettering Cancer Center), Marinela Capanu(Memorial Sloan Kettering Cancer Center), Hans Gerdes(Memorial Sloan Kettering Cancer Center), Mark Schattner(Memorial Sloan Kettering Cancer Center), Marc Simmons(Memorial Sloan Kettering Cancer Center), Mario E. Lacouture(Memorial Sloan Kettering Cancer Center), Viktoriya Paroder(Memorial Sloan Kettering Cancer Center), Laura H. Tang(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), David H. Ilson(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center)
The Lancet Oncology
September 1, 2023
Cited by 44Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis